8-K: Simulations Plus Reports Strong Second Quarter Fiscal 2025 Results, Revenue Up 23%

Simulations Plus announces a 23% year-over-year increase in total revenue for Q2 2025, driven by growth in both software and services, while maintaining full-year revenue guidance.

Summary

• Simulations Plus reported a 23% increase in total revenue for the second quarter of fiscal year 2025, reaching $22.4 million.
• Software revenue grew by 16% to $13.5 million, representing 60% of total revenue, while services revenue increased by 34% to $8.9 million, accounting for 40% of total revenue.
• The company's gross profit was $13.1 million with a gross margin of 59%.
• Net income was $3.1 million, resulting in a diluted EPS of $0.15, compared to $4.0 million and $0.20, respectively, in the prior year's quarter.
• Adjusted EBITDA was $6.6 million, representing 29% of total revenue, compared to $7.1 million, or 39% of total revenue, in the same quarter last year.
• Adjusted net income was $6.2 million, with an adjusted diluted EPS of $0.31, versus $6.4 million and $0.32 in the prior year.
• For the first six months of fiscal 2025, total revenue increased by 26% to $41.4 million.
• The company maintains its full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20.
• The company's backlog ended the quarter at $20.4 million, a 13% year-over-year increase.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong revenue growth and maintained guidance, but some declines in profitability metrics temper the overall sentiment.

Positives

• Strong revenue growth of 23% in Q2 2025, driven by both software and services.
• Significant expansion in the QSP business unit, with 89% revenue growth.
• Backlog increased by 13% year-over-year, indicating future revenue potential.
• The company is on track to achieve its stated guidance for fiscal year 2025.
• Cheminformatics revenues increased by 8%, while Clinical Pharmacology & Pharmacometrics (CPP) business unit posted a 9% revenue increase.

Negatives

• Net income decreased to $3.1 million from $4.0 million in the same quarter last year.
• Diluted EPS decreased to $0.15 from $0.20 in the same quarter last year.
• Adjusted EBITDA margin decreased to 29% from 39% in the same quarter last year.
• Adjusted net income decreased to $6.2 million from $6.4 million in the same quarter last year.
• Adjusted diluted EPS decreased to $0.31 from $0.32 in the same quarter last year.

Risks

• The company's ability to integrate its Adaptive Learning & Insights (ALI) and Medical Communications (MC) business units could impact future performance.
• The general economics of the pharmaceutical industry and macroeconomic factors could affect the company's results.
• The company's ability to finance growth and attract/retain qualified staff are ongoing risks.
• Market conditions and acceptance of new software versions by customers could influence future performance.
• Ongoing cost constrained and limited funding environment for biopharma customers.

Future Outlook

The company maintains its fiscal year 2025 revenue guidance of $90 million to $93 million, representing 28-33% growth, with a software mix of 55-60%, an adjusted EBITDA margin of 31-33%, and adjusted diluted EPS of $1.07 to $1.20.

Management Comments

• Shawn OConnor, CEO, stated that the company delivered strong performance in Q2 2025 with total revenue growing by 23%.
• Shawn OConnor noted the outstanding execution across all software platforms, with QSP leading growth at 89%.
• Shawn OConnor mentioned the solid performance in the first half of the year despite the cost-constrained environment for biopharma customers.
• Shawn OConnor believes the company is well-positioned to maintain momentum and achieve its stated guidance.

Industry Context

Simulations Plus operates in the cheminformatics, biosimulation, and medical communications sectors, serving the biopharmaceutical industry. The company's performance reflects the ongoing demand for simulation and modeling solutions in drug discovery and development, despite a cost-conscious environment.

Comparison to Industry Standards

• It's difficult to provide a direct comparison without knowing the specific peer group Simulations Plus benchmarks against.
• However, companies like Certara and Schrödinger are also key players in the modeling and simulation space.
• Certara, for example, focuses on biosimulation and regulatory science, while Schrödinger emphasizes computational chemistry and materials science.
• Simulations Plus's growth rate and profitability should be compared against these and other relevant companies to assess its relative performance.
• The company's adjusted EBITDA margin of 29% should be compared to industry averages to determine its efficiency and profitability relative to peers.

Stakeholder Impact

• Shareholders can expect continued growth and profitability, with the company on track to meet its financial guidance.
• Employees can anticipate opportunities for growth and development within the expanding organization.
• Customers will benefit from the company's continued investment in innovative software and services.
• Suppliers can expect continued business relationships with a financially stable and growing company.

Next Steps

• The company will continue to focus on delivering consistent revenue growth and profitability.
• Simulations Plus will optimize its business unit structure following recent strategic acquisitions.
• The company will focus on supporting accelerated growth in its distributor network.
• Simulations Plus will continue to develop its organization to drive growth and create shareholder value.

Key Dates

Keywords

Simulations Plus, Financial Results, Revenue Growth, Software, Services, Biosimulation, QSP, EBITDA, EPS, Guidance